Through Northern Eyes: Robert E. Lee and the Northern Press

Most historians would agree that it is an anomaly in history how Robert E. Lee became an American icon. General Lee was the commander of a rebel army that was trying to split the country he had once loyally served into two. Even after being defeated at the Battle of Appomattox, instead of Lee suffering the normal fate of all failed revolutionaries, he was pardoned and allowed to continue to live in his native Virginia. Over a short amount of time after General Lee’s death he was elevated from rebel to hero. The origins of this can be traced back to the Civil War when General Lee was given accolades in the country’s newspapers he was fighting against. Due to the way the Northern Press regarded Lee this must be considered the base for understanding how the people of the North came to view General Lee not as a traitor, but as an American icon

Governing mobilities on the UK canal network

This paper examines mobility governance in an environment where varied mobility practices occur. Drawing on a quasi-ethnography of canal users in England and Wales, we discuss how multiple mobilities (including boating, walking, cycling and running) are practised in the relatively confined and linear spaces of canals and adjacent towpaths, and often at the same time. We demonstrate how these different yet intertwined modes of movement, and their associated tempos, are governed through creative interplays of freedom and control, and hierarchy and etiquette. These findings give rise to wider questions regarding the potentialities of governmobility – i.e. a system in which mobilities are able to govern themselves. Our conclusion, therefore, explores how the governance of mobilities on the UK canal network might offer insight, or a ‘watery blueprint’, for mobility governance in other shared spaces. This includes exploring the debates between giving citizens greater freedom and agency to negotiate their own mobility juxtapositions and tensions, versus imposing upon them stricter rule-based systems of mobility regulation

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5], and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 35–<50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.gov; Unique identifier: NCT01663402.URL: https://www

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes